Meboflur Cukormentes Narancsízu

Flurbiprofen, the active ingredient in Meboflur Cukormentes Narancsízu, is a non‑steroidal anti‑inflammatory drug (NSAID) presented as an oropharyngeal preparation for local use. It is indicated for relief of sore throat, oral mucosal inflammation, and mild to moderate pain in the oropharyngeal region.

GNH USA supplies Meboflur Cukormentes Narancsízu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Flurbiprofen acts on inflammatory pathways in the oropharyngeal region, providing symptomatic relief for several common conditions. - Sore throat: reduces pain and inflammation, facilitating easier swallowing. - Oral mucosal inflammation: diminishes swelling and erythema of the oral lining. - Mild to moderate oropharyngeal pain: alleviates discomfort associated with minor injuries or infections.

Flurbiprofen may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Taste alteration: temporary metallic or bitter sensation in the mouth. - Local irritation: mild burning or tingling at the site of application. - Nausea: occasional feeling of queasiness. - Headache: mild to moderate intensity. - Dyspepsia: mild stomach discomfort.

Serious or Rare Side Effects: - Gastrointestinal ulceration: rare bleeding or ulcer formation in the stomach or intestine. - Allergic reaction: rash, itching, or swelling of the face, lips, or tongue. - Severe bronchospasm: difficulty breathing in susceptible individuals. - Hepatic dysfunction: elevated liver enzymes indicating liver stress. - Renal impairment: reduced kidney function or acute kidney injury.

Before using Meboflur Cukormentes Narancsízu, consider the following safety measures. - Contraindication: avoid in patients with known hypersensitivity to flurbiprofen or other NSAIDs. - Caution: use carefully in individuals with a history of peptic ulcer disease or gastrointestinal bleeding. - Monitoring: assess renal and hepatic function in patients with pre‑existing kidney or liver disorders. - Interaction awareness: inform healthcare provider of concurrent anticoagulant or antiplatelet therapy. - Pregnancy and lactation: consult a physician, as safety data are limited. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Flurbiprofen can interact with several medicines; awareness of the interaction level helps manage risk.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of serious bleeding. - Selective COX‑2 inhibitors (e.g., celecoxib): additive gastrointestinal toxicity. - Corticosteroids: heightened chance of ulceration and bleeding. - Lithium: NSAIDs may raise lithium serum concentrations. - Methotrexate (high dose): reduced clearance leading to toxicity.

Moderate Interactions (Monitor Closely): - Antihypertensives (e.g., ACE inhibitors, diuretics): possible reduction in antihypertensive effect. - Diuretics: potential for reduced renal perfusion. - SSRIs (e.g., sertraline): modest increase in bleeding risk. - Alcohol: may exacerbate gastrointestinal irritation. - Allopurinol: rare reports of enhanced nephrotoxicity.